KYL

Product Name:KYL

CAS No:676657-00-4

Purity:95%

Molar Mass:1465.73

Chemical Formula:C74H108N14O17

Storage:Store at -20 degrees Celsius

Sequence:KYLPYWPVLSSL

Target:EphA4

Application:

KYL is a peptide that acts as an antagonist of the EphA4 receptor, a member of the Eph receptor tyrosine kinase family. EphA4 plays a critical role in the regulation of various cellular processes, including cell adhesion, migration, and synaptic plasticity, making it relevant in neurobiology and cancer research. KYL is often used in studies to block the interaction between EphA4 and its ephrin ligands, offering insights into pathways involved in nerve regeneration, neurodegenerative diseases, and tumor progression. By inhibiting EphA4 activity, KYL is valuable for exploring therapeutic strategies targeting EphA4-related pathways.

Current Research:

KYL peptide (CAS: 676657-00-4) is a synthetic 12-amino-acid peptide that functions as an antagonist of the EphA4 receptor tyrosine kinase. By binding to the ligand-binding domain of EphA4, KYL peptide inhibits its interaction with ephrin ligands, thereby modulating various cellular processes.

Mechanism of Action

KYL peptide selectively targets the EphA4 receptor, binding to its ligand-binding domain with a dissociation constant (K_d) of approximately 0.8 μM. This interaction effectively inhibits EphA4-ephrinA5 binding, with an IC₅₀ of about 6.34 μM. By blocking EphA4 activation, KYL peptide can prevent downstream signaling pathways involved in synaptic function and plasticity.

Neuroprotective Effects

In models of Alzheimer's disease, KYL peptide has demonstrated the ability to alleviate amyloid-beta oligomer (AβO)-induced synaptic dysfunction. It prevents dendritic spine loss and rescues long-term potentiation (LTP) deficits in hippocampal CA3-CA1 transmissions, indicating its potential in preserving synaptic integrity.

Potential Therapeutic Applications

Due to its inhibitory effects on EphA4, KYL peptide is being explored for therapeutic applications in neurodegenerative diseases, spinal cord injuries, and conditions involving aberrant EphA4 signaling. Its ability to modulate immune responses further broadens its potential clinical utility.

Conclusion

KYL peptide serves as a valuable tool in research focused on EphA4-mediated signaling pathways. Its neuroprotective properties and capacity to promote nerve regeneration highlight its promise as a therapeutic agent for various neurological conditions.

Reference:

Wu, B., Zhang, Z., Noberini, R., Barile, E., Giulianotti, M., Pinilla, C., ... & Pellecchia, M. (2013). HTS by NMR of combinatorial libraries: a fragment-based approach to ligand discovery. Chemistry & biology, 20(1), 19-33.